ABBV vs NKTR
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. NKTR: Nektar Therapeutics is a clinical-stage biotechnology company developing first-in-class immunomodulatory therapies aimed at restoring immune system balance to treat chronic autoimmune and inflammatory disorders.
Side-by-side fundamentals
| Metric | ABBV | NKTR | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $264.96 | $74.02 | |
| Market cap as of 2026-08-24 | $468.2B | $2.5B | |
| P/E as of 2026-08-24 | 70.24 | n/a | |
| PEG as of 2026-08-24 | 6.59 | n/a | |
| Net margin as of 2026-08-24 | +9.8% | -280.8% | ABBV higher |
| Gross margin as of 2026-08-24 | +72.8% | +100.0% | NKTR higher |
| Operating margin as of 2026-08-24 | +26.2% | -242.0% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | -45.8% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | -40.3% | ABBV higher |
| Debt / equity as of 2026-08-24 | 49.22 | 0.10 | NKTR lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | -36.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -15.7% | ABBV higher |
| Dividend yield as of 2026-08-24 | +4.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.22 | 1.23 | |
| 1-year return as of 2026-08-21 close | +26.5% | +164.4% | NKTR higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.